A health worker vaccinates an elderly woman with the Abdala vaccine in August 2021. Photo: AFP
–
At the end of December 15, they accumulate in the country 29 126 523 doses administered with the Cuban vaccines Soberana-02, Soberana Plus and Abdala.
To date, 10,235,340 people have received at least one dose of one of the Cuban vaccines Soberana-02, Soberana Plus and Abdala (those vaccinated with Soberana Plus as a single dose are included). Of these, 9,275,241 people already have a second dose, and a third, 8,870,275 people.
9,402,992 people have a complete vaccination scheme, 84.1% of the Cuban population.
A total of 745,667 people have booster doses, of them 71,353 as part of the clinical study and 659,395 as part of the booster vaccination that is being applied to the population of selected territories and risk groups.
Mass vaccination
The Center for the State Control of Medicines, Equipment and Medical Devices (Cecmed) on July 9 decided to grant the authorization of emergency use (AUE) to the Cuban vaccine Abdala 50 µg, whose owner is the Center for Genetic Engineering and Biotechnology ( CIGB), in accordance with the provisions of current regulations and provisions, once it has been confirmed that the requirements and parameters demanded in terms of quality, safety and efficacy for this type of procedure were met.
On August 20, Cecmed decided to grant the emergency use authorization to the Cuban vaccines Soberana 02 and Soberana Plus, whose owner is the Finlay Vaccine Institute, in accordance with the provisions of current regulations and provisions, once confirmed that the requirements and parameters demanded in terms of quality, safety and efficacy for this type of procedure were met.
Start date: July 29, 2021
Participants:
- Population over 19 years of age in territories with epidemiological risk and risk groups at the level of all provinces.
- Pediatric population from 2 to 18 years of age throughout the country.
Total doses administered during Mass Vaccination: 18 716 095
Clinical study
After the approval of the booster dose strategy, the clinical study with vaccine candidates (Soberana 01 and Mambisa) and the start of vaccination with a fourth dose was approved, starting with health workers and risk groups.
* These booster doses are added to the number of doses applied in the country in its accumulated.
Start date: November 2021
Participants:
- Health workers
- Population of selected territories
- Other risk groups
Total doses administered during the clinical study: 71 353
Health intervention
Since the beginning of May, the Minister of Public Health, backed by Article 64 of Law 41, Public Health Law, of July 13, 1983, approved a health intervention with the Cuban vaccine candidates Abdala and Soberana 02 in groups and risk territories.
Start date: mayo 2021
Participants:
- Health workers, BioCubaFarma, Medical Sciences students and other risk groups.
- Population of territories at risk selected by stages.
Total doses administered during the health intervention: 9 618 545
Intervention study
As part of the research associated with the Cuban vaccine candidates Soberana 02 and Abdala, an intervention study was carried out in risk groups, aimed at subjects in risk groups and who could provide relevant data.
Start date: March 2021
Participants: health workers, BioCubaFarma and other risk groups.
Territories where the study was applied: Havana, Santiago de Cuba, Granma and Guantánamo.
Total doses administered during the intervention study: 454 064
Clinical trials
The development of clinical trials with the Cuban vaccine candidates Soberana 02, Abdala and Soberana Plus (for convalescents) was approved by Cecmed and implemented in volunteer subjects from selected territories.
Start date: March 2021
Participants: volunteer subjects selected by researchers.
Territories where the tests were applied: Havana, Santiago, Granma and Guantánamo.
Total doses administered during clinical trials: 266 466 (placebo doses administered during clinical trials are excluded from this figure).
(With information from Minsap)
– .
